Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mogamulizumab + Durvalumab/Tremelimumab in Solid Tumors
NCT02301130Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Nov 2014
- Primary completion
- Dec 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of mogamulizumab in solid tumor (advanced stage) (2 arms), sponsored by Kyowa Kirin. Primary endpoints: Number of subjects reporting adverse events, Number of subjects reporting serious adverse events and 1 more. Started Nov 2014; status: completed.
02
Drugs
mogamulizumab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02301130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02301130.